Shots: Accent to receive ~$446M including up front, pre-clinical, clinical, regulatory, and sales-based milestone along with royalties Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage […]readmore
Tags : AML
Shots: The EC approval is based on a P-III QUAZAR AML-001 study assessing Onureg (300mg, qd) vs PBO + BSC for 14days of a 28-day cycle in patients aged ≥55yrs. […]readmore
Shots: EMA’s COMP has granted ODD to SLS-005 for the treatment of amyotrophic lateral sclerosis Under ODD, Seelos will get benefit from several incentives such as protocol assistance, reduced regulatory […]readmore
Shots: The approval is based on P-III VIALE-A and P-Ib M14-358 studies. The P-III study involves assessing Venclyxto + azacitidine in patients with newly diagnosed AML who were ineligible for […]readmore
Shots: The companies enter into a supply agreement for Alemtuzumab to be used in Cellectis’ trials as a lymphodepleting regimen for UCART22 in the BALLI-01 clinical trial to treat r/r […]readmore
Shots: The CHMP has recommended the approval of Opdivo (nivolumab) + Yervoy (ipilimumab) as 1L treatment for unresectable MPM and is based P-III CheckMate -743 trial that met its 1EPs […]readmore
Shots: Interim analysis of the ongoing P-III study of pracinostat + azacitidine in patients with AML who are unfit to receive CT demonstrated that it was unlikely to meet its […]readmore